(Brentuximab vedotin) Takeda

Composition:
• Available in 50 mg powder for concentrate for solution for infusion

Indications:
• Newly indicated for the treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD)

• Also indicated for adult patients with :

   • CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT)

   • relapsed or refractory CD30+ HL following ASCT or at least 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

   • CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy

• Used in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adults patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or relapsed or refractory sALCL

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.